Compare SID & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SID | AMLX |
|---|---|---|
| Founded | 1941 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2002 | 2021 |
| Metric | SID | AMLX |
|---|---|---|
| Price | $1.25 | $16.21 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $1.40 | ★ $20.11 |
| AVG Volume (30 Days) | ★ 7.2M | 872.5K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $2.50 | N/A |
| Revenue Next Year | $2.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $1.11 | $3.11 |
| 52 Week High | $2.20 | $17.49 |
| Indicator | SID | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 65.11 |
| Support Level | $1.17 | $12.29 |
| Resistance Level | $1.30 | $17.22 |
| Average True Range (ATR) | 0.05 | 0.81 |
| MACD | 0.02 | 0.26 |
| Stochastic Oscillator | 65.79 | 96.55 |
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations in railways and port terminals. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.